resultados positivos partner y gran grafico. dentro. mirarla pleas,e a ver que tal la veis.
saludos a todos.
Novavax reported that its partner, Genocea Biosciences, announced positive, interim topline data from a phase 1/2A clinical trial of its lead candidate, GEN-003. Genocea's herpes simplex virus-2 therapeutic vaccine candidate uses the Novavax proprietary adjuvant known as Matrix-M. Genocea's results showed that vaccination with GEN-003 potentiated by the Matrix-M adjuvant can significantly blunt HSV-2 infection and reduce viral shedding. The two highest dose cohorts, both adjuvanted with Matrix-M, demonstrated significant reductions in viral shedding. No serious adverse events were related to the vaccine.